Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | PRKDC | P78527 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 2/20 | 0.31 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.31 |
| ▸ | TSHR | P16473 | 2/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
| ▸ | RECQL | P46063 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9489951 | 0.72 | KDM4E (0.37) | PRKDCMAPTALDH1A1CYP1A2RECQL | |
| SCHEMBL40342 | 0.69 | TNKS (0.35) | PRKDCMAPTALDH1A1SMN1; SMN2 | |
| SCHEMBL39726 | 0.69 | MAPT (0.49) | GAAPRKDCMAPTALDH1A1TSHR | |
| SCHEMBL21047591 | 0.64 | PRKDC (0.40) | PRKDCMAPTALDH1A1RECQLPOLB | |
| SCHEMBL16470749 | 0.63 | ALDH1A1 (0.36) | GAAMAPTALDH1A1TSHRRECQL | |
| SCHEMBL27668135 | 0.62 | MAPT (0.38) | GAAMAPTALDH1A1RECQLPOLB | |
| SCHEMBL3349858 | 0.62 | ALDH1A1 (0.41) | GAAPRKDCMAPTALDH1A1POLB | |
| SCHEMBL761104 | 0.62 | — | — | |
| SCHEMBL39665 | 0.62 | KDM4E (0.35) | GAAPRKDCMAPTALDH1A1RECQL | |
| SCHEMBL21047699 | 0.62 | PRKDC (0.35) | PRKDCMAPTALDH1A1TSHRPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3682947-A1 | COMPOUNDS AND METHODS FOR REGULATING INTEGRIN CD11B/CD18 | GB006, Inc. (US) | 2020-07-22 | — | — | EP | disclosed |
| EP-3243821-B1 | PHARMACEUTICAL FORMULATIONS FOR REGULATING INTEGRIN CD11B/CD18 | GB006 INC (US) | 2020-02-26 | — | — | EP | disclosed |
| CN-106038558-B | Compounds and methods for modulating integrin CD11b/CD18 | GB006公司 | 2020-01-10 | — | — | CN | disclosed |
| EP-3243821-A1 | PHARMACEUTICAL FORMULATIONS FOR REGULATING INTEGRIN CD11B/CD18 | Adhaere Pharamaceuticals, Inc. (US) | 2017-11-15 | — | — | EP | disclosed |
| EP-2591092-B1 | COMPOUNDS AND METHODS FOR REGULATING INTEGRIN CD11B/CD18 | ADHAERE PHARAMACEUTICALS INC (US) | 2017-06-21 | — | — | EP | disclosed |
| CN-106038558-A | Compounds and methods for regulating integrin CD11B/CD18 | 阿德黑雷制药公司 | 2016-10-26 | — | — | CN | disclosed |
| CN-103189500-B | Compounds and methods for modulating integrin CD11b/CD18 | 阿德黑雷制药公司 | 2016-06-15 | — | — | CN | disclosed |
| US-9023876-B2 | Compounds and methods for regulating integrins | ADHAERE PHARMACEUTICALS, INC. (US) | 2015-05-05 | — | — | US | disclosed |
| EP-2591092-A1 | COMPOUNDS AND METHODS FOR REGULATING INTEGRIN CD11B/CD18 | Adhaere Pharamaceuticals, Inc. (US) | 2013-05-15 | — | — | EP | disclosed |
| US-20120010255-A1 | Compounds and Methods for Regulating Integrins | ATEGRIN, INC. | 2012-01-12 | — | — | US | disclosed |
| WO-2012005800-A1 | COMPOUNDS AND METHODS FOR REGULATING INTEGRIN CD11B/CD18 | ADHAERE PHARAMACEUTICALS, INC. (US) | 2012-01-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120010255-A1 | Compounds and Methods for Regulating Integrins | ITGB8, ITGB3, ITGAM | CNR1 1192/4885GAA 4195/4885PRKDC 4533/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.